Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

A new community-led network called PRADA enables underrepresented patients living with MS to help set research priorities.

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and ...

UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...

A collaboration will test whether changes in a person’s voice can help detect multiple sclerosis, potentially enabling a ...

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

After struggling during seasons when MS took center stage, columnist Ahna Crum is enjoying the quieter days where it's only ...

MS pain is the uninvited guest you can't turn away, columnist Desiree Lama writes. Listening to your body is the key to ...

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

Immunic raised funds to support Phase 3 clinical trials of vidofludimus calcium for MS and transition into a commercial-stage company.

A type of immune cell targeting the Epstein-Barr virus may play a key role in driving multiple sclerosis (MS), a study found.

Some MS diets may help lower inflammation marker levels, but evidence from clinical trials remains limited, according to a new review paper.